Payment overview · 2025
General Payments
$739.72
45 reported records · 15 companies
Healthcare provider profile · identity verified
Christopher S Johnson, MD
Allopathic & Osteopathic Physicians|Family Medicine · ROGERS, AR · NPI 1508824871
Verified facts
What the public records show
CMS Open Payments records show Christopher S Johnson, MD received $739.72 in general payments during 2025 across 45 reported records.
PFIZER INC. accounted for 38.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Linzess by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Myrbetriq by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $281.74 | 38.1% | 16 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $75.51 | 10.2% | 4 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $65.82 | 8.9% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $60.24 | 8.1% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $42.60 | 5.8% | 3 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $34.77 | 4.7% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $33.85 | 4.6% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $30.68 | 4.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $29.77 | 4.0% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.78 | 2.4% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $16.34 | 2.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.11 | 2.2% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $15.12 | 2.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.65 | 1.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $5.74 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $739.72 | 45 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $177.60 | 12 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $177.60 | 12 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $104.14 | 4 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $104.14 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $104.14 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $75.51 | 4 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $65.82 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $42.60 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $42.60 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $38.31 | 2 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $34.77 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $33.85 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $31.05 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $30.68 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $29.77 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $29.19 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.19 | 2 | 2025 |
Source payment records
|
|||||
| FLUZONE QUADRIVALENT NORTHERN HEMISPHERE Normalized: fluzone quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $19.63 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.78 | 1 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $16.34 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.11 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $15.12 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $14.50 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.65 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.65 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $5.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 136 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 54 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
54 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
136 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
128 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 476 | 140 |
| Losartan Potassium | Losartan Potassium | 405 | 121 |
| Levothyroxine Sodium | Levothyroxine Sodium | 318 | 83 |
| Lisinopril | Lisinopril | 308 | 85 |
| Amlodipine Besylate | Amlodipine Besylate | 305 | 90 |
| Gabapentin | Gabapentin | 282 | 81 |
| Omeprazole | Omeprazole | 235 | 72 |
| Trazodone Hcl | Trazodone Hcl | 198 | 62 |
| Metoprolol Succinate | Metoprolol Succinate | 197 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 181 | 54 |
| Pravastatin Sodium | Pravastatin Sodium | 179 | 51 |
| Zolpidem Tartrate | Zolpidem Tartrate | 176 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 175 | 53 |
| Metformin Hcl | Metformin Hcl | 167 | 47 |
| Metformin Hcl Er | Metformin Hcl | 160 | 44 |
| Simvastatin | Simvastatin | 144 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 138 | 40 |
| Ozempic | Semaglutide | 136 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 136 | 45 |
| Tramadol Hcl | Tramadol Hcl | 136 | 32 |
| Eliquis | Apixaban | 128 | 24 |
| Furosemide | Furosemide | 124 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 119 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 108 | 25 |
| Prednisone | Prednisone | 104 | 39 |
| Fluoxetine Hcl | Fluoxetine Hcl | 101 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 95 | 28 |
| Potassium Chloride | Potassium Chloride | 95 | 26 |
| Alendronate Sodium | Alendronate Sodium | 94 | 29 |
| Carvedilol | Carvedilol | 90 | 25 |
| Clonazepam | Clonazepam | 87 | 16 |
| Meloxicam | Meloxicam | 86 | 24 |
| Spironolactone | Spironolactone | 75 | 18 |
| Famotidine | Famotidine | 69 | 19 |
| Farxiga | Dapagliflozin Propanediol | 69 | 23 |
| Xarelto | Rivaroxaban | 65 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 64 | 18 |
| Allopurinol | Allopurinol | 63 | 22 |
| Alprazolam | Alprazolam | 59 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 59 | 17 |
| Glimepiride | Glimepiride | 59 | 20 |
| Sertraline Hcl | Sertraline Hcl | 57 | 18 |
| Memantine Hcl | Memantine Hcl | 55 | 14 |
| Baclofen | Baclofen | 54 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 54 | 14 |
| Pregabalin | Pregabalin | 53 | suppressed |
| Finasteride | Finasteride | 52 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 52 | 21 |
| Estradiol | Estradiol | 51 | 16 |
| Atenolol | Atenolol | 49 | 12 |
| Mirtazapine | Mirtazapine | 49 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | 13 |
| Montelukast Sodium | Montelukast Sodium | 47 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 46 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 43 | 19 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 40 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 39 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 37 | 16 |
| Promethazine Hcl | Promethazine Hcl | 36 | suppressed |
| Ezetimibe | Ezetimibe | 35 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 35 | suppressed |
| Topiramate | Topiramate | 35 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 34 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Rivastigmine | Rivastigmine | 32 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 31 | 14 |
| Cholestyramine | Cholestyramine (With Sugar) | 31 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 14 |
| Nifedipine Er | Nifedipine | 31 | suppressed |
| Ondansetron Odt | Ondansetron | 31 | 20 |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | 11 |
| Irbesartan | Irbesartan | 27 | suppressed |
| Lorazepam | Lorazepam | 27 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 26 | suppressed |
| Jardiance | Empagliflozin | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | 12 |
| Azithromycin | Azithromycin | 24 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 13 |
| Digoxin | Digoxin | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $739.72 · 45 records | PFIZER INC. | ABRYSVO, BEYFORTUS, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, EVENITY, FLUZONE QUADRIVALENT NORTHERN HEMISPHERE, Heplisav-B, MOUNJARO, NEXPLANON, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, PROLIA, QULIPTA, REPATHA, Rybelsus, SKYCLARYS, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, Veozah, XIFAXAN, ZAVZPRET, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error